James Motyka
Biographic Data
| ID | 7144340 |
|---|---|
| NAME | James Motyka |
| GIVEN NAMES | James |
| FAMILY NAME | Motyka |
| SIGNATURE | MOTYKA J |
| AFFILIATIONS | National Pharmaceutical Council, Washington, DC, USA |
| ORCID | 0009-0006-9216-0141 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
The Association of the 340B Program with Affordable Care Act (ACA) Premiums
We tested whether the 340B program impacts Affordable Care Act (ACA) premiums. Data from 2018 to 2022 was used to establish a baseline for silver benchmark premiums and other key measures, including: the number of active 340B sites per 10,000 people in a county (Hospital Site Density, or HSD), ACA benchmark plan premiums for every county, and measures likely to influence insurance premiums including per capita income, unemployment, and hospital m…
The Association of 340B Program Drug Margins with Covered Entity Characteristics
The 340B Drug Pricing Program aims to help facilities serving low-income and uninsured patients to stretch scarce resources by allowing covered entities to purchase outpatient drugs at federally mandated discounted rates while often receiving reimbursement for them at higher rates by commercial payers and Medicare. Despite increasing focus on the expansion and impact of the program, profit margins under 340B have not been fully explored. We aimed…
No prominent works on this page.
The Association of the 340B Program with Affordable Care Act (ACA) Premiums
We tested whether the 340B program impacts Affordable Care Act (ACA) premiums. Data from 2018 to 2022 was used to establish a baseline for silver benchmark premiums and other key measures, including: the number of active 340B sites per 10,000 people in a county (Hospital Site Density, or HSD), ACA benchmark plan premiums for every county, and measures likely to influence insurance premiums including per capita income, unemployment, and hospital m…
The Association of 340B Program Drug Margins with Covered Entity Characteristics
The 340B Drug Pricing Program aims to help facilities serving low-income and uninsured patients to stretch scarce resources by allowing covered entities to purchase outpatient drugs at federally mandated discounted rates while often receiving reimbursement for them at higher rates by commercial payers and Medicare. Despite increasing focus on the expansion and impact of the program, profit margins under 340B have not been fully explored. We aimed…
Actuarial science (2 works) · Economic growth (2 works) · Economics (2 works) · Health care (2 works) · Healthcare cost, quality, practices (2 works) · Healthcare Policy and Management (2 works) · Medicine (2 works) · Business (1 work) · Demographic economics (1 work) · Demography (1 work)